Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yu Sung Yang
Observed names:
Y Yang,
Yang Yu,
Yu YANG,
Yu Yang
Institution:
Fujian Provincial Cancer Hospital
Observed institutions:
Shenyang Pharmaceutical University,
Fujian Medical University,
Shanghai Jiao Tong University,
Shanghai Chest Hospital,
Presbyterian Medical Center,
Fujian Provincial Hospital,
Fujian Provincial Cancer Hospital
show all 7
ORCID:
0000-0002-3513-8865
Observed ORCID:
0000-0002-3513-8865
OpenAlex ID:
A5040300450
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
·
Clinical Cancer Research
·
52
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
2025
·
Yan Gao
, Yunhong Huang
, et al.
·
Cancer
·
17
PDF
ADP-ribosylation, a multifaceted modification: Functions and mechanisms in aging and aging-related diseases
2024
·
Wu Hao
, Zhao Jialong
, et al.
·
Ageing Research Reviews
·
14
Bendamustine in the treatment of patients with indolent non‐Hodgkin lymphoma refractory or relapse to rituximab treatment: An open‐label, single‐agent, multicenter study in China
2022
·
Yan Gao
, Yizhen Liu
, et al.
·
Cancer
·
3
Evaluation and patient selection for minimally invasive esophagectomy
2018
·
Yifeng Sun
, Yang Yang
, et al.
·
Shanghai Chest
·
2
Clinical Experience with a Hybrid Procedure Using the Adherent Clot Catheter for Salvage of Thrombosed Hemodialysis Access: A Comparison with the Standard Fogarty Balloon Catheter
2015
·
Yu Sung Yang
, Kyu Dam Han
, et al.
·
Vascular Specialist International
·
2
Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study
2025
·
Gao Yan
, Huijing Wu
, et al.
·
Blood
·
1
PDF
Expanded Forehead Stepped Flaps for Delayed Three-Stage Repair of Midface Skin Lesions
2020
·
Shengwu ZHENG
, Xiongmei HUANG
, et al.
·
Chinese Journal of Plastic and Reconstructive Surgery
·
1
PDF
Results of Absorbable Mesh Insertion and Patient Satisfaction in Breast-Conserving Surgery
2017
·
Ei Young Kwon
, Yu Sung Yang
, et al.
·
Journal of Breast Disease
·
1
PDF
Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
626 a Neural Circuit for Vagal Afferent-initiated Gastric Nociceptive Signaling
2024
·
Fu-Chao Zhang
, Yong-Chang Li
, et al.
·
Gastroenterology
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
Show more works
View as search
Works count:
49
Citation count:
93
H-index:
3
I10-index:
3
Year
Topic
Type